HFNC Effect on BCSS in Patients With COPD (COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02825043|
Recruitment Status : Terminated (Slow enrollment and unable to meet enrollment targets)
First Posted : July 7, 2016
Results First Posted : June 29, 2020
Last Update Posted : June 29, 2020
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Device: High-Flow Nasal Cannula||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of High-Flow Nasal Cannula (HFNC) on the Breathlessness, Cough, and Sputum Scale (BCSS), in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|
|Actual Study Start Date :||February 2016|
|Actual Primary Completion Date :||November 21, 2018|
|Actual Study Completion Date :||November 21, 2018|
Experimental: High Flow Nasal Cannula Participants
High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
Device: High-Flow Nasal Cannula
This is a humidified oxygen delivery system.
Other Name: AIRVO 2 Series Humidifier
- Changes in Breathlessness, Cough and Sputum Scale (BCSS) [ Time Frame: 6 months ]The Changes in Breathlessness, Cough and Sputum Scale (BCSS) is a three question measure consisting of three questions, each rated on a scale of "0" to "4", with a total possible score ranging from 0-12. Zero equals no difficulty and four equals severe difficulty or constant problem. A lower score on the scale is a better outcome.
- Change in Number of Chronic Obstructive Pulmonary Disease Exacerbations Per Month [ Time Frame: 6 months ]The number of chronic obstructive pulmonary disease exacerbations per month will be monitored throughout the study. A lower number of chronic obstructive pulmonary disease exacerbations are considered improvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02825043
|United States, Oklahoma|
|University of Oklahoma|
|Oklahoma City, Oklahoma, United States, 73104|
|Principal Investigator:||Karen Allen, MD||OUMC|